Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 2,409 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Invasive Procedure Clear all

Conditions: Aspergillosis
Interventions: Voriconazole, micafungin; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Little Rock, Arkansas

Conditions: Alzheimer Disease
Interventions: transcranial alternating current stimulation (tACS); Device
Lead sponsor: Hebrew SeniorLife; Other
Eligibility: 21 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Urothelial Cancer, Cancer, Bladder Neoplasms, Urinary Bladder Cancer
Interventions: Not listed
Lead sponsor: Lahey Clinic; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2028
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Invasive Fungal Infection
Interventions: Posaconazole IV 6 mg/kg, Posaconazole PFS 6 mg/kg; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 1 Day to 2 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 5
States / cities: San Diego, California • Miami, Florida • Chicago, Illinois + 2 more

Conditions: Uterine Neoplasms, Leiomyoma
Interventions: Self-hypnotic relaxation; Behavioral
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 90 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Soft Tissue Neoplasms
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Peripheral Neuropathy
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 99 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Body Fat
Interventions: TempSure; Device
Lead sponsor: Cynosure, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 6
States / cities: Hunt Valley, Maryland • New York, New York • Rye, New York + 3 more

Conditions: Breast Cancer
Interventions: intracavitary balloon brachytherapy, intraoperative radiation therapy; Radiation
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 3
States / cities: Cleveland, Ohio

Conditions: Breast Neoplasms, Breast Diseases, Breast Fibroadenoma, Breast Cancer
Interventions: Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine); Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Invasive Mechanical Ventilation
Interventions: Artificial Intelligence-based Decision support; Other
Lead sponsor: Technische Universität Dresden; Other
Eligibility: 18 Years and older
Enrollment: 318,542 participants
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma
Interventions: Anastrozole, Exemestane, Fulvestrant, Letrozole, Paclitaxel, Talimogene Laherparepvec, Tamoxifen, Nab paclitaxel, Gemcitabine, Carboplatin; Drug · Biological
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hematologic Malignancy, Myeloproliferative Disorder
Interventions: Isavuconazole; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Urothelial Carcinoma, Muscle Invasive Bladder Urothelial Carcinoma, Non-Muscle Invasive Bladder Urothelial Carcinoma
Interventions: Not listed
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Omaha, Nebraska • Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Ultrasound; Device
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 20 Years to 90 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Fetal Growth Restriction, Preeclampsia Severe
Interventions: Expanded panel cell free DNA testing (non-invasive prenatal testing), Placental biopsy, Umbilical cord blood; Genetic
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 70 participants
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer
Interventions: cyclophosphamide, docetaxel, doxorubicin hydrochloride, Trastuzumab, Carboplatin, Paclitaxel; Drug · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Amblyopia
Interventions: Sham Transcranial Random Noise Stimulation, High Frequency Transcranial Random Noise Stimulation; Device
Lead sponsor: Midwestern University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Downers Grove, Illinois

Conditions: Pelvic Organ Prolapse, Post Operative Pain
Interventions: Quadratus Lumborum (QL) Block, Enhanced Recovery After Surgical (ERAS) Protocol; Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Sleep, Sleep Disturbance
Interventions: Elemind Neuromodulation (ENMod); Device
Lead sponsor: Elemind Technologies, Inc.; Industry
Eligibility: 21 Years to 55 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Substance-Related Disorders, Substance Use Disorders, Substance Abuse, Intravenous, Substance Withdrawal, Substance Abuse, Opioid-use Disorder, Opioid Use Disorder, Severe, Opioid Use
Interventions: Non invasive VN stimulation (nVNS), Oxygen (15-O) Water, Sham Stimulation; Device · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Aortic Valve Disease, Aortic Valve Replacement
Interventions: Standard of Care plus Enhanced Patient Education, Motivational Interviewing Intervention, Home-Based Activity Program plus Motivational Interviewing Intervention; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Complex Regional Pain Syndrome (CRPS)
Interventions: transcranial alternating current stimulation (tACS); Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Chronic Fatigue Syndrome, Myalgic Encephalomyelitis, Exercise Intolerance, Dysautonomia, Low Ventricular Filling Pressures (Preload Failure), Postural Orthostatic Tachycardia Syndrome, Orthostatic Hypotension, Fibromyalgia
Interventions: Pyridostigmine Bromide, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis

Memory Functions in Mild Alzheimer's Disease

Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer

Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)

Self-Hypnotic Relaxation Therapy During Invasive Procedures

Radiofrequency Ablation of Painful Soft Tissue Neoplasms

In Vivo Corneal Confocal Microscopy for Non-invasive Assessment of Diabetic Peripheral Neuropathy

Multi-Center Pivotal Study of Radiofrequency Device

Radiation Therapy in Treating Patients With Recurrent Breast Cancer

Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)

Evaluation and Further Development of an Artificial Intelligence-based Algorithm for Clinical Decision Support

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)

Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)

VisR Ultrasound for Noninvasively Interrogating Stromal Collagen Organization in Women as a Breast Cancer Biomarker: Evaluation of Anisotropy in Cancer Patients

Expanded NIPT for Pregnancy Complications

Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer

Noninvasive Brain Stimulation in Adult Amblyopia

Postoperative Pain Management Following Robotic Assisted Sacrocolpopexy

Sounds Locked to ElectroEncephalogram Phase For the Acceleration of Sleep Onset Time

Non-Invasive Vagal Nerve Stimulation in Opioid Use Disorders

Optimization Post-TAVR to IMprove Activity Levels (OPTIMAL Study)

Effects of Non-invasive Brain Stimulation on Pain Avoidance Behavior in Chronic Pain Patients

The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome